- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| Do | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.07. | Polyrizon Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 22.07. | Polyrizon Stock Jumps 53% On Positive Preclinical Results For Allergy Blocker | 1 | RTTNews | ||
| 22.07. | Polyrizon-Aktie steigt nach positiven Studiendaten für Allergie-Nasenspray stark an | 4 | Investing.com Deutsch | ||
| 22.07. | Polyrizon stock soars after promising nasal allergy blocker test results | 5 | Investing.com | ||
| 22.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.07. | Polyrizon meldet vielversprechende Ergebnisse für nasalen Allergenblocker | 2 | Investing.com Deutsch | ||
| 22.07. | Polyrizon's nasal allergy blocker shows promising deposition results | 1 | Investing.com | ||
| 22.07. | Polyrizon Ltd.: Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study | 104 | GlobeNewswire (Europe) | Ra'anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 16.07. | Polyrizon Stock Slides After Hours After 52% Surge On Tuesday: Why It Moved | 1 | Benzinga.com | ||
| 15.07. | Polyrizon Shares Jump Over 38% After Securing Nasdaq Listing Extension | 2 | RTTNews | ||
| 15.07. | Polyrizon retains Nasdaq listing following hearings panel | 2 | Seeking Alpha | ||
| 15.07. | Polyrizon secures continued Nasdaq listing after panel hearing | 2 | Investing.com | ||
| 15.07. | Polyrizon sichert sich nach Anhörung Verbleib an der NASDAQ | 2 | Investing.com Deutsch | ||
| 15.07. | Polyrizon Ltd.: Polyrizon Retains Nasdaq Listing Following Hearings Panel | 239 | GlobeNewswire (Europe) | Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 15.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.06. | Polyrizon-Direktor Omer Srugo tritt zurück; Vorstand bestätigt unabhängige Mitglieder | 1 | Investing.com Deutsch | ||
| 30.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.06. | Polyrizon Ltd.: Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics | 1 | GlobeNewswire (USA) | ||
| 12.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,240 | +0,27 % | Qiagen übertrifft Erwartungen in 2Q - Prognose für Gesamtjahr angehoben | DJ Qiagen übertrifft Erwartungen in 2Q - Prognose für Gesamtjahr angehoben
DOW JONES--Qiagen hat mit den Ergebnissen für das zweite Quartal die Erwartungen übertroffen und den Ausblick für das... ► Artikel lesen | |
| NOVAVAX | 5,881 | +0,72 % | Novavax Q2 2025 Earnings Preview | ||
| PALATIN TECHNOLOGIES | 0,281 | 0,00 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,310 | +3,15 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,360 | 0,00 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
| XOMA ROYALTY | 21,200 | -10,17 % | XOMA Royalty Corporation Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right | EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ: XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,124 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,320 | -2,11 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds | King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 1,245 | 0,00 % | Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development | SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
| VIVUS | - | - | Vivus' Qsymia gains market approval in UAE for obesity treatment | ||
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,529 | -8,37 % | Windtree Therapeutics: Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients | Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses... ► Artikel lesen | |
| SERES THERAPEUTICS | 12,500 | -2,19 % | Uncovering Potential: Seres Therapeutics' Earnings Preview |
POLYRIZON LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,140 Euro und damit -2,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.